×
Mannatech EBIT 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Mannatech ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
Mannatech EBIT 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Mannatech ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$72B
Zoetis (ZTS)
$69.3B
Takeda Pharmaceutical (TAK)
$47.7B
Daiichi Sankyo, - (DSNKY)
$45.3B
BeOne Medicines - (ONC)
$33.5B
Sandoz Group AG (SDZNY)
$27.7B
Summit Therapeutics (SMMT)
$17.6B
Merck (MKKGY)
$16.4B
Shionogi (SGIOY)
$14.6B
Neurocrine Biosciences (NBIX)
$13.8B
United Therapeutics (UTHR)
$13.7B
IPSEN (IPSEY)
$11.4B
Orion OYJ (ORINY)
$11.2B
Madrigal Pharmaceuticals (MDGL)
$9.7B
Eisai (ESAIY)
$8.9B
Corcept Therapeutics (CORT)
$7.3B
Stevanato Group S.p.A (STVN)
$7B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.8B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.7B
Hypermarcas (HYPMY)
$2.7B
Procaps Group, S.A (PROCF)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$2.1B